"Weight-loss miracle drugs" discounting growth space? Research found that 75% of patients stopped taking the medicines within two years.

wallstreetcn ·  Jul 10 21:26

Source: Wall Street See

Research has found that only a few patients can adhere to long-term use of GLP-1 weight loss drugs, and the huge potential for growth of "miracle weight loss drugs" may have to be discounted.

On July 10th, according to Reuters, only a quarter of American patients continue to take Wegovy or Ozempic weight loss drugs two years after treatment, and the analysis also shows that patients' drug usage decreases steadily over time.$Novo-Nordisk A/S (NVO.US)$After treatment with Wegovy or Ozempic weight loss drugs, patients continued to take them two years later, and the analysis also showed that the amount of medication used by patients steadily decreased over time.

Prime Therapeutics and Magellan Rx Management reviewed pharmacy and medical claims data for 3,364 commercially insured GLP-1 drug patients. These patients all received new prescriptions between January and December 2021 and were diagnosed as obese or having a BMI of over 30.

The analysis found that 32% of patients were still taking GLP-1 drugs after 12 months of use, which decreased to 15% two years later.

For Wegovy, 24.1% of patients continued to take the drug uninterrupted for more than two years, lower than the 36% for one year. For Ozempic, 22.2% of patients continued to take the drug for more than two years, lower than the 47.1% for one year. The situation for older GLP-1 drugs was even worse, with only 7.4% of patients still taking the drug two years later.

The analysis did not indicate the specific reasons for patients stopping the medication, but provided actual medication experience that lasts longer than one year, which is less than previous research. This result affects the debate over its cost to patients, employers, and government health plans.

Wegovy and Ozempic belong to the GLP-1 receptor agonist class of drugs, which may cost more than $1,000 per month and may require long-term use to achieve significant effects.

Novo Nordisk indicated the limitations of the analysis in a statement, stating that Wegovy was launched in June 2021 during the study period and was not initially covered by insurance; Ozempic was not approved for weight loss, which may affect patients' insurance coverage and continued use. The company said that these data are not sufficient to draw conclusions about patients' overall adherence and persistence with various GLP-1 drugs.

Regarding the reasons for patients stopping medication, Dr. Patrick Gleason, Assistant Vice President for Health Business at Prime, responsible for health business, said that possible reasons include nausea and vomiting side effects, out-of-pocket costs not covered by insurance, and supply shortages. Some patients may decide to stop taking the drug after successfully losing weight, and other studies have shown that most patients who stop taking the drug usually regain most of their weight after stopping.

Editor / jayden

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment